Original Research

Published on 13 Feb 2023

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy

in Thoracic Oncology

Michael R. Sayer
Isa Mambetsariev
Kun-Han Lu
Chi Wah Wong
Ashley Duche
Richard Beuttler
Jeremy Fricke
Rebecca Pharoan
Leonidas Arvanitis
Zahra Eftekhari

Frontiers in Oncology

doi 10.3389/fonc.2023.1064169

3,318 views
7 citations

Editorial

Published on 09 Feb 2023

Editorial: Factors that impact the survival of non-small cell lung cancer

in Thoracic Oncology

Fiona Hegi-Johnson
Kristin A. Higgins

Frontiers in Oncology

doi 10.3389/fonc.2023.1148340

1,098 views

Original Research

Published on 09 Feb 2023

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer

in Thoracic Oncology

Greta Alì
Anello Marcello Poma
Iosè Di Stefano
Carmelina Cristina Zirafa
Alessandra Lenzini
Giulia Martinelli
Gaetano Romano
Antonio Chella
Editta Baldini
Franca Melfi

Frontiers in Oncology

doi 10.3389/fonc.2023.1115156

4,866 views
6 citations

Mini Review

Published on 08 Feb 2023

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer

in Thoracic Oncology

Xiaofei Zhang
Jianguo Zhang
Peiyi Liu
Juan Wang
Kuaile Zhao
Zhengfei Zhu
Kangsheng Gu
Weixin Zhao

Frontiers in Oncology

doi 10.3389/fonc.2023.1022042

3,583 views
3 citations

Systematic Review

Published on 08 Feb 2023

Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis

in Thoracic Oncology

Mingbo Tang
Yifeng Shao
Junxue Dong
Xinliang Gao
Shixiong Wei
Jianzun Ma
Yang Hong
Zhiqin Li
Taiyu Bi
Yipeng Yin

Frontiers in Oncology

doi 10.3389/fonc.2023.1061264

2,893 views
3 citations

Original Research

Published on 07 Feb 2023

Safety and efficacy of stereotactic ablative brachytherapy as a salvage therapy for recurrent chest wall cancer: A retrospective, multicenter study

in Thoracic Oncology

Bin Huo
Zhe Ji
Chuang He
Wanying Yang
Yanli Ma
Xiaodong Huo
Zhe Wang
Xinxin Zhao
Jinchao Dai
Haitao Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.957497

1,739 views
1 citation

Case Report

Published on 06 Feb 2023

Case report: Primary mediastinal Ewing’s sarcoma presenting with chest tightness

in Thoracic Oncology

Manman Cui
Duchang Zhai
Yan Liu
Xiuzhi Zhou
Tingting Wang
Lihuan Wang
Wu Cai
Guohua Fan
Shenghong Ju

Frontiers in Oncology

doi 10.3389/fonc.2022.1020339

2,295 views
3 citations

Original Research

Published on 02 Feb 2023

Distinct respiratory microbiota associates with lung cancer clinicopathological characteristics

in Thoracic Oncology

Xi Zheng
Xingbing Lu
Yang Hu

Frontiers in Oncology

doi 10.3389/fonc.2023.847182

2,550 views
9 citations

Case Report

Published on 02 Feb 2023

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report

in Thoracic Oncology

Alessandro Inno
Emanuela Lattuada
Giovanni Foti
Stefania Gori

Frontiers in Oncology

doi 10.3389/fonc.2023.1053497

1,319 views

Original Research

Published on 31 Jan 2023

Preoperative prognostic prediction for stage I lung adenocarcinomas: Impact of the computed tomography features associated with the new histological grading system

in Thoracic Oncology

Min Liang
Wei Tang
Fengwei Tan
Hui Zeng
Changyuan Guo
Feiyue Feng
Ning Wu

Frontiers in Oncology

doi 10.3389/fonc.2023.1103269

1,611 views
2 citations

Original Research

Published on 26 Jan 2023

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center

in Thoracic Oncology

Yicheng Xiong
Dongliang Bian
Zhida Huang
Huansha Yu
Jie Huang
Peng Zhang
Wenxin He
Hongcheng Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1034897

1,889 views
2 citations

Review

Published on 26 Jan 2023

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone

in Thoracic Oncology

Wen-Fang Tang
Hong-Yu Ye
Xuan Tang
Jian-Wei Su
Kang-Mei Xu
Wen-Zhao Zhong
Yi Liang

Frontiers in Oncology

doi 10.3389/fonc.2023.1063183

15,197 views
17 citations

Original Research

Published on 26 Jan 2023

What is the appropriate “first lymph node” in the era of segmentectomy for non-small cell lung cancer?

in Thoracic Oncology

Joseph Seitlinger
Florent Stasiak
Juliette Piccoli
Gabriele Maffeis
Arthur Streit
Christophe Wollbrett
Joelle Siat
Guillaume Gauchotte
Stéphane Renaud

Frontiers in Oncology

doi 10.3389/fonc.2022.1078606

2,356 views
2 citations

Case Report

Published on 26 Jan 2023

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies

in Thoracic Oncology

Chiara Lazzari
Mona Rita Yacoub
Corrado Campochiaro
Alessandra Bulotta
Diego Palumbo
Francesca Rita Ogliari
Lorenzo Dagna
Silvia Marchesi
Maurilio Ponzoni
Vanesa Gregorc

Frontiers in Oncology

doi 10.3389/fonc.2023.1079034

2,325 views
2 citations

Case Report

Published on 26 Jan 2023

Extraskeletal Ewing’s sarcoma of the mediastinum: Case report

in Thoracic Oncology

Aldo Caltavituro
Roberto Buonaiuto
Fabio Salomone
Rocco Morra
Erica Pietroluongo
Pietro De Placido
Marianna Tortora
Annarita Peddio
Fernanda Picozzi
Margaret Ottaviano

Frontiers in Oncology

doi 10.3389/fonc.2023.1074378

2,575 views
6 citations

Case Report

Published on 25 Jan 2023

Case Report: A case of synchronous right upper lobe adenocarcinoma and left lower lobe squamous cell carcinoma treated with immune checkpoint inhibitor plus chemotherapy

in Thoracic Oncology

Yujiao Liu
Han Yu
Youhong Dong
Dongdong Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1062138

1,121 views

Navigation group

Articles

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy

Editorial: Factors that impact the survival of non-small cell lung cancer

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer

Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis

Safety and efficacy of stereotactic ablative brachytherapy as a salvage therapy for recurrent chest wall cancer: A retrospective, multicenter study

Case report: Primary mediastinal Ewing’s sarcoma presenting with chest tightness

Distinct respiratory microbiota associates with lung cancer clinicopathological characteristics

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report

Preoperative prognostic prediction for stage I lung adenocarcinomas: Impact of the computed tomography features associated with the new histological grading system

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone

What is the appropriate “first lymph node” in the era of segmentectomy for non-small cell lung cancer?

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies

Extraskeletal Ewing’s sarcoma of the mediastinum: Case report

Case Report: A case of synchronous right upper lobe adenocarcinoma and left lower lobe squamous cell carcinoma treated with immune checkpoint inhibitor plus chemotherapy